However, like any groundbreaking medication with much potential, GLP-1s do come with some uncertainties, mainly around cost and sustainability
25 Both affinity and activity reduce 10-fold if the Arg 36 of GLP-1 is cut away, 41 showing that it is crucial for interaction
L-carnitine L-tartrate is a compound combining L-carnitine with tartaric acid, and it is one of the forms typically used in powder-based supplements of this kind
Data sources The input parameters for the benefit-harm balance modelling were the relative treatment effects of GLP-1 RAs as compared to placebo, the benefit and harm outcome incidences in untreated individuals, and preference weights (relative importance) of the outcomes.24, 25, 26, 27 A careful selection of valid and applicable evidence relevant to the given decision context is a key step in a benefit-harm analysis.28, 29, 30 The relative treatment effect and baseline risks were obtained from RCTs